Texas Permanent School Fund Invests $549,000 in Artivion, Inc. (NYSE:AORT)

Texas Permanent School Fund purchased a new position in Artivion, Inc. (NYSE:AORTGet Rating) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 29,057 shares of the company’s stock, valued at approximately $549,000. Texas Permanent School Fund owned approximately 0.07% of Artivion as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Assetmark Inc. acquired a new position in shares of Artivion in the second quarter worth about $26,000. Nisa Investment Advisors LLC acquired a new position in shares of Artivion in the second quarter worth about $65,000. Los Angeles Capital Management LLC acquired a new stake in Artivion during the second quarter valued at approximately $214,000. State Board of Administration of Florida Retirement System acquired a new stake in Artivion during the second quarter valued at approximately $440,000. Finally, M&T Bank Corp acquired a new stake in Artivion during the second quarter valued at approximately $435,000. Institutional investors and hedge funds own 85.18% of the company’s stock.

Artivion Stock Performance

Shares of NYSE AORT opened at $12.65 on Tuesday. The stock has a fifty day moving average price of $13.26 and a two-hundred day moving average price of $17.32. The company has a debt-to-equity ratio of 1.22, a quick ratio of 3.59 and a current ratio of 5.17. The firm has a market cap of $510.16 million, a P/E ratio of -12.16 and a beta of 1.36. Artivion, Inc. has a 1 year low of $9.64 and a 1 year high of $23.43.

Analyst Ratings Changes

Several brokerages have issued reports on AORT. Needham & Company LLC cut their price objective on Artivion from $28.00 to $23.00 and set a “buy” rating on the stock in a research note on Friday, November 4th. Oppenheimer lowered their target price on Artivion from $35.00 to $25.00 and set an “outperform” rating for the company in a report on Monday, September 26th. Lake Street Capital lowered their target price on Artivion from $32.00 to $28.00 and set a “buy” rating for the company in a report on Tuesday, September 27th. Finally, Morgan Stanley lowered their target price on Artivion from $16.00 to $14.00 and set an “equal weight” rating for the company in a report on Tuesday, October 11th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Artivion Company Profile

(Get Rating)

Artivion Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo.

Further Reading

Want to see what other hedge funds are holding AORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artivion, Inc. (NYSE:AORTGet Rating).

Institutional Ownership by Quarter for Artivion (NYSE:AORT)

Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.